Empyrean Neuroscience Launches With $22M Series A And Genetic Engineering Platform To Advance Pipeline Of Neuroactive Compounds Targeting Cns Disorders
Amount Raised
$22 Million
Round Type
Series A
Description
Empyrean Neuroscience, Inc., a leading genetic engineering company dedicated to developing neuroactive compounds to treat neuropsychiatric and neurologic disorders, today announced that it has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company is founded on a proprietary platform designed to genetically engineer small molecule therapeutics from fungi and plants. Veteran biotech executives Usman “Oz” Azam, M.D., Chief Executive Officer, and Fred Grossman, D.O., FAPA, Chief Medical Officer, lead the company.
Quick answer
Empyrean Neuroscience raised $22 Million in a Series A round, dated October 18, 2022. Empyrean Neuroscience is based in New York, United States.
- How much did Empyrean Neuroscience raise?
- Empyrean Neuroscience raised $22 Million in a Series A round on October 18, 2022.
- What does Empyrean Neuroscience do?
- Empyrean Neuroscience is a genetic engineering company developing a pipeline of neuroactive therapeutics to treat a range of neuropsychiatric and neurologic disorders.
- Where is Empyrean Neuroscience based and how big is it?
- Empyrean Neuroscience is based in New York, United States.
Source: Fundz verified event record.
Who to call at Empyrean Neuroscience, and when
A new round usually means Empyrean Neuroscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Empyrean Neuroscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Empyrean Neuroscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Empyrean Neuroscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Empyrean Neuroscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansEmpyrean Neuroscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.